Breaking Ground: Aruna Bio Unveils Promising Preclinical Findings in Pilot Study for Amyotrophic Lateral Sclerosis Treatment AB126

Hope on the Horizon: Aruna Bio’s Breakthrough Preclinical Results Offer Potential ALS Treatment

BOSTON and ATHENS, Ga., Sept. 07, 2023 (GLOBE NEWSWIRE) — Aruna Bio, Inc., a trailblazer in neural exosome-based therapies for neurodegenerative diseases, has unveiled promising preclinical findings. In a pilot study evaluating AB126 for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), a rare genetic form of ALS, the results are nothing short of groundbreaking.

Administering a weekly dose of AB126 from the onset of ALS symptoms through the study’s conclusion led to remarkable outcomes. It not only extended the survival of the subjects but also significantly reduced inflammation in the spinal cord, outperforming the vehicle group. Additionally, AB126-treated animals exhibited lower levels of neurofilament light chain in their serum compared to those treated with the vehicle.

AB126, an unaltered neural-derived exosome, possesses a unique ability to breach the blood-brain barrier. It achieves this by modulating the inflammasome within the central nervous system (CNS) through newly-discovered anti-inflammatory and neuroprotective mechanisms.

Stephen From, CEO of Aruna Bio, expressed optimism about their findings, saying, “We are encouraged by our growing dataset demonstrating the potential of AB126 in its native form to address both acute and chronic neurological indications, including ALS, a progressive neurodegenerative disease with an average survival of three to five years.”

From emphasized the study’s positive results, highlighting prolonged survival and significant reductions in inflammatory mediators and serum neurofilament light chain. He also shared plans to expand their AB126 platform for chronic CNS conditions, offering renewed hope to patients and their families.

About Aruna Bio

At the forefront of neurodegenerative disease treatment, Aruna Bio is rewriting the future of healthcare. Armed with their proprietary neural exosome platform and cutting-edge manufacturing capabilities, the company is charting a course to develop a remarkable lineup of neural exosome-based therapies.

These innovative treatments possess a unique ability to transcend the blood-brain barrier, unlocking the body’s natural anti-inflammatory, self-repair, and protective mechanisms. They hold the promise to revolutionize the landscape of neurodegenerative disorders, addressing critical unmet medical needs.

What sets Aruna Bio apart is the versatility of their neural exosome platform. It seamlessly combines with other therapeutics, including small molecules, siRNAs, and proteins, to navigate the complex terrain of the blood-brain barrier. Together, they reach the heart of the disease, offering renewed hope to those in need.

Leave a Comment